Open-label placebos and stress during the COVID-19 pandemic. A randomized controlled trial.

Open-label placebos and stress during the COVID-19 pandemic. A randomized controlled trial. - CORST

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027476

Enrollment

100

Registered

2021-12-27

Start date

2021-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress, Anxiety

Interventions

Group 1: The treatment group receives a placebo for three weeks (two each day). Group 2: Control group (no placebo)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy participants, who claim to feel stress and anxiety due to the Corona pandemic

Exclusion criteria

Exclusion criteria: known history of psychiatric or neurologic diseases; pregnancy

Design outcomes

Primary

Measure	Time frame
Feelings of being stressed (VAS scores) at the beginning and after 3 weeks	—

Secondary

Measure	Time frame
Health-related quality of life (SF-12) at the beginning and after 3 weeks	—

Countries

Germany

Contacts

Public ContactMichael Schaefer

Medical School Berlin

michael.schaefer@medicalschool-berlin.de0306117542

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026